Investment Company - Sixty Degree Capital

We help founders transform industries.

Venture investment in technology and healthcare

GLOBAL MULTI-STAGE INVESTOR, WORLD-CLASS NETWORK

Approach

Sixty Degree Capital invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO).

Advantage

We have a world-class network, specialized in-house expertise, and relationships with marquee investors. This differentiation enables us to support our portfolio companies and generate exceptional returns for our investors.

Our Portfolio

All

Technology

Healthcare

All

Technology

Healthcare

Blog/News

News

KITE AND ARCELLX ANNOUNCE STRATEGIC COLLABORATION TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA

By pwsbuilder | June 22, 2023

— Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing — SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for…

By pwsbuilder | June 22, 2023

January 09, 2023 02:05 ET| Source: CinCor Pharma IncFollow WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the…

By pwsbuilder | June 22, 2023

HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers. The company will host a live-stream event featuring both its co-founder and CEO discussing the breakthrough significance of SCINTIX…

By Sixty Degree Capital | November 23, 2023

November 23, 2023 – Sixty Degree Capital is excited to announce the final close of its third venture capital fund, with $250M earmarked for high-growth companies from Series A to pre-IPO stages across enterprise software and healthcare.Fund III is already actively deploying capital to industry-leading ventures including Cato Networks, Docker, NextPoint, Strive Health, Navan, Aqua…

By pwsbuilder | June 22, 2023

– Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021 August 02, 2021 08:00 ET| Source: T-knife Therapeutics SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for…

By pwsbuilder | June 22, 2023

Existing investors NEA, Oak HC/FT and Alta Partners, and new investors, including Endeavor Catalyst, joined the round Funding will accelerate growth, enhance Everside’s technology stack to facilitate predictive, whole-patient care, and support potential M&A opportunities DENVER, July 25, 2022 /PRNewswire/ — Everside Health, LLC, a leading national direct primary care provider, today announced that it has raised $164 million in growth equity funding. Longstanding investor…

We help founders transform industries.

GLOBAL MULTI-STAGE INVESTOR, WORLD-CLASS NETWORK

Approach

Advantage

Our Portfolio

Blog/News

News

KITE AND ARCELLX ANNOUNCE STRATEGIC COLLABORATION TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA

By pwsbuilder | June 22, 2023

CinCor Pharma to be Acquired by AstraZeneca

By pwsbuilder | June 22, 2023

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

By pwsbuilder | June 22, 2023

Sixty Degree Capital Celebrates Final Close of Fund III, Raising $250M for VC Investment in High-Growth Tech Companies

By Sixty Degree Capital | November 23, 2023

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

By pwsbuilder | June 22, 2023

Everside Health Announces $164 Million in Growth Equity Funding from NEA and New Investors

By pwsbuilder | June 22, 2023

KITE AND ARCELLX ANNOUNCE STRATEGIC COLLABORATION TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA

By pwsbuilder | June 22, 2023

CinCor Pharma to be Acquired by AstraZeneca

By pwsbuilder | June 22, 2023

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

By pwsbuilder | June 22, 2023

Sixty Degree Capital Celebrates Final Close of Fund III, Raising $250M for VC Investment in High-Growth Tech Companies

By Sixty Degree Capital | November 23, 2023

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

By pwsbuilder | June 22, 2023

Everside Health Announces $164 Million in Growth Equity Funding from NEA and New Investors

By pwsbuilder | June 22, 2023

Michelle Yao

Senior Analyst at Sixty Degree Capital

Michelle Yao

Senior Analyst at Sixty Degree Capital

Greater Toronto Area, Canada

Overview

Work Experience

Sixty Degree Capital

Senior Analyst

2020 - Current

KPMG Canada

Senior Associate

2018 - 2020

Fosun 复星

Senior Investment Manager

2015 - 2018

Relevant Websites